CoChat
Sign Up
Cited by 108Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsLung Cancer Research Studies

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Open access
Socinski, M.A., Langer, C.J., Okamoto, I., Hon, J.K., Hirsh, V., Dakhil, S.R., Page, R.D., Orsini, J. +2 more·2013·Annals of Oncology
DOI 10.1093/annonc/mds461
Open this paper in CoChat — free account

Abstract

Background This analysis evaluates safety and efficacy in elderly (≥ 70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer (NSCLC) trial.Patients and methods Untreated stage IIIB/IV patients with PS 0/1 were randomly assigned (1:1) to carboplatin AUC6, day 1 every 3 weeks, and either nab-paclitaxel (Abraxane) 100 mg/m(2) weekly (nab-P/C) or solvent-based paclitaxel (Taxol) 200 mg/m(2) day 1 every 3 weeks (sb-P/C). The primary end-point was overall response rate (ORR).Results Fifteen percent of 1052 enrolled patients were elderly: nab-P/C, n = 74; sb-P/C, n = 82. In both age cohorts, the ORR was higher with nab-P/C versus sb-P/C (age ≥ 70: 34% versus 24%, P = 0.196; age <70: 32% versus 25%, P = 0.013). In elderly patients, progression-free survival (PFS) trended in favor of nab-P/C (median 8.0 versus 6.8 months, hazard ratio (HR) 0.687, P = 0.134), and overall survival (OS) was significantly improved (median 19.9 versus 10.4 months, HR 0.583, P = 0.009). In younger patients, PFS (median 6.0 versus 5.8 months, HR 0.903, P = 0.256) and OS (median 11.4 versus 11.3 months, HR 0.999, P = 0.988) were similar in both arms. Adverse events were similar in both age groups, with less neutropenia (P = 0.015), neuropathy (P = 0.001), and arthralgia (P = 0.029), and increased anemia (P = 0.007) with nab-P/C versus sb-P/C.Conclusions In elderly NSCLC patients, nab-P/C as first-line therapy was well tolerated and improved the ORR and PFS, with substantially longer OS versus sb-PC.

Integrity signals

Registry

Crossref · 10.1093/annonc/mds461

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Socinski, M. A., Langer, C. J., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Zhang, H., & Renschler, M. F.
Affiliations
  • University of Pittsburgh Medical Center (US)
  • Fox Chase Cancer Center (US)
  • Kindai University (JP)
  • Clearview Cancer Institute (US)
  • McGill University (CA)
  • Cancer Center of Kansas (US)
  • Center for Cancer and Blood Disorders (US)
  • Celgene (United States) (US)
Corresponding author
Socinski, M.A.
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2013-02
Volume
24
Issue
2
Pages
314-321
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mds461
OpenAlex
W2119038990
Cited by
108
References
25
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 9 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 22 · 2014: 12 · 2013: 8
FWCI
10.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Celgene Corporation, Summit, NJ, USA
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
non-small cell lung cancer, nab-paclitaxel, carboplatin, elderly patients, first-line therapy, weekly paclitaxel, overall response rate, progression-free survival, overall survival, adverse events, neutropenia, neuropathy, anemia, age comparison, paclitaxel, stage IIIB/IV NSCLC
MeSH terms
Adult, Aged, Aged, 80 and over, Aging, Albumins, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neutropenia, Survival Rate, Carboplatin, Treatment Outcome, Paclitaxel, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review